Reps, Jenna M. http://orcid.org/0000-0002-2970-0778
Williams, Ross D.
You, Seng Chan
Falconer, Thomas
Minty, Evan
Callahan, Alison
Ryan, Patrick B.
Park, Rae Woong
Lim, Hong-Seok
Rijnbeek, Peter
Funding for this research was provided by:
Health Promotion Administration, Ministry of Health and Welfare (HI16C0992)
Innovative Medicines Initiative Joint Undertaking (806968)
Article History
Received: 9 July 2019
Accepted: 23 April 2020
First Online: 6 May 2020
Ethics approval and consent to participate
: All patient data included in this study were deidentified.The New England Institutional Review Board determined that studies conducted in Optum, IBM CCAE, IBM MDCR, and IBM MDCD are exempt from study-specific IRB review, as these studies do not qualify as human subjects research.CUMC, STRIDE and AUSOM had institutional review board approval for the analysis, or used deidentified data, and thus the analysis was determined not to be human subjects research and informed consent was not deemed necessary at any site.
: Not applicable.
: Jenna Reps is an employee of Janssen Research & Development and shareholder of Johnson & Johnson. Patrick Ryan is an employee of Janssen Research & Development and shareholder of Johnson & Johnson. Peter Rijnbeek works for a research group who received unconditional research grants from Boehringer-Ingelheim, GSK, Janssen Research & Development, Novartis, Pfizer, Yamanouchi, Servier. None of these grants result in a conflict of interest to the content of this paper.